Syremis Therapeutics
Syremis Therapeutics is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel and Boston, Massachusetts, developing best-in-class oral small-molecule medicines for serious mental health conditions. Its neuropsychiatric pipeline is rooted in clinically validated mechanisms including muscarinic M1/M4 agonism and next-generation NMDA antagonism; lead program ST-905 is a dual M1/M4 agonist in Phase 1 for schizophrenia, with ST-901 also spun out from Clexio Biosciences. The company launched publicly in December 2025 with a $165M Series A co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet. Surfaced in the API Evangelist network as a portfolio company of GV. This company publishes no public API, developer, or event surface at this time.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Syremis Therapeutics the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Syremis Therapeutics scores 7.7/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Syremis Therapeutics
Each block below is one kind of artifact we hold for Syremis Therapeutics. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Syremis Therapeutics — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API
← All providers · Data indexed from github.com/api-evangelist/syremis-therapeutics · machine-readable index on apis.io